• Marie Kostine, Aurélien Marabelle, Thierry Schaeverbeke, and Maria Kfoury.
• Service de rhumatologie, hôpital Pellegrin, Bordeaux, France.
• Med Sci (Paris). 2019 Dec 1; 35 (12): 949-956.

AbstractImmunotherapeutic strategies, notably immune checkpoint inhibitors, have become a standard of care for the treatment of advanced cancers, with a growing spectrum of activity. These monoclonal antibodies target the co-inhibitory signals between tumor cells or antigen-presenting cells and T cells, thereby enhancing antitumour T cell activity. However, the occurrence of immune-related adverse events, that can affect all organ-system, represents a major limiting factor to the clinical development of these antibodies. Management of such toxicity requires a close collaboration between oncologists and organ-specialists, by using glucocorticoids and/or other immunosuppressive therapies, with the common objective not alter anti-tumor response.© 2019 médecine/sciences – Inserm.

23 keywords...

hide…